Answers are grounded in this paper and cite their sources.
Background: To establish a volume-dependent statistical framework for evaluating the quality of stereotactic radiotherapy (SRT) and radiosurgery (SRS) plans, while identifying the specific target volume thresholds where non-coplanar volumetric modulated arc therapy (VMAT) outperforms conventional three-dimensional conformal radiotherapy (3D-CRT) in healthy tissue sparing. Materials and methods: A retrospective analysis of 453 treatment plans for brain tumours and vascular malformations (2018–2023) was performed. Plans were categorised by technique: 3D-CRT (n = 311), non-coplanar VMAT (n = 108), and coplanar VMAT (n = 34). Eight dosimetric indices, including the Radiation Therapy Oncology Group (RTOG) and Paddick conformity indices, gradient index, and equivalent fall-off distance (EFOD), were evaluated. Given the physics of small-field geometry, metrics were modelled as functions of the natural logarithm of the target volume [ln(TV)] or the fourth root of the target volume (∜TV). Institutional reference ranges were established using ±1 and ±2 standard deviations from the regression-derived expected values. Results: VMAT demonstrated superior and more consistent conformity across the volume spectrum. However, crossover points were identified at target volumes of 1.1 cm 3 for the normal-brain volume receiving 10 Gy (V10Gy) and 0.8 cm 3 for the normal-brain volume receiving 12 Gy (V12Gy). Below these thresholds, 3D-CRT provided superior sparing of healthy tissue due to its sharper dose fall-off in very small fields. The EFOD was confirmed as a highly reliable predictor of dose gradient, showing a linear correlation (R = 0.99) with ∜TV. Approximately 5% of the study population fell outside the specified interval, validating the sensitivity of these thresholds as dosimetric quality indicators. Conclusions: This study provides objective, volume-specific benchmarks that move beyond diameter-based safety limits. By incorporating these statistical reference values into an automated, colour-coded assessment tool, the proposed framework may support technique selection, plan review, and standardisation of stereotactic plan quality. However, these thresholds should be interpreted as institutional dosimetric quality assurance (QA) benchmarks, and prospective clinical validation is required before they can be directly linked to toxicity reduction or patient outcomes.
No takes yet. Share an insight, caveat, or question.
Janiszewska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: